Every pregnant mother worries whether her baby will be healthy. But invasive tests for genetic abnormalities — chorionic villus sampling and amniocentesis – present a small risk of miscarriage.

In a groundbreaking development, genetics experts at Jerusalem’s Shaare Zedek Medical Center have devised a patent-pending process to screen a fetus for genetic diseases using a blood sample from the mother. A paper just published in the Journal of Clinical Investigation describes how it works.

Dr. Gheona Altarescu, director of Shaare Zedek’s Preimplantation Genetic Unit, tell that chemical pathologist Dennis Lo discovered in 1997 that small pieces of fetal DNA float freely in the mother’s bloodstream. This led to the development of prenatal blood tests for chromosomal abnormalities such as Down syndrome. However, these tests cannot detect monogenic genetic diseases such as Tay-Sachs and cystic fibrosis, even if the parents are carriers of the defective gene.

The next development in this field of noninvasive prenatal testing was to detect not only the chromosomes of the baby but also mutations coming from the father.

“You can test for a genetic disease passed [only] by the father, because if you can detect it in the sample taken from the pregnant mother, it has to be from the fetus,” she says. “We took it a step further, developing an algorithm to detect diseases coming also from the mother, which is much more complicated.”

Altarescu worked in collaboration with computational biologist David Zeevi; neurologist Dr. Arndt Rolfs, CEO of Centogene-The Rare Disease Company, in Germany; and Dr. Ari Zimran, director of the Gaucher Clinic at Shaare Zedek.